Based on the measurements of operating efficiency obtained from Lexaria Bioscience's historical financial statements, Lexaria Bioscience Corp is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, Lexaria Bioscience's Liabilities And Stockholders Equity is fairly stable compared to the past year. Non Current Liabilities Total is likely to rise to about 209.8 K in 2024, whereas Property Plant And Equipment Net is likely to drop slightly above 370.1 K in 2024. Key indicators impacting Lexaria Bioscience's financial strength include:
The financial analysis of Lexaria Bioscience is a critical element in measuring its lifeblood. Investors should not minimize Lexaria Bioscience's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income
(5.51 Million)
Lexaria
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Average Inventory
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Other Cashflows From Financing Activities
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Begin Period Cash Flow
Depreciation
Other Non Cash Items
Change To Account Receivables
Stock Based Compensation
Change To Inventory
Investments
Net Borrowings
Total Cashflows From Investing Activities
Change To Operating Activities
Change To Netincome
Change To Liabilities
Issuance Of Capital Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Common Stock
Short Long Term Debt Total
Current Deferred Revenue
Net Receivables
Short Term Debt
Inventory
Non Currrent Assets Other
Intangible Assets
Net Tangible Assets
Net Invested Capital
Net Working Capital
Property Plant Equipment
Short Term Investments
Accumulated Other Comprehensive Income
Capital Stock
Capital Lease Obligations
Depreciation And Amortization
Interest Expense
Other Operating Expenses
Operating Income
Ebit
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Total Revenue
Gross Profit
Cost Of Revenue
Selling General Administrative
Selling And Marketing Expenses
Research Development
Net Interest Income
Net Income From Continuing Ops
Reconciled Depreciation
Net Income Applicable To Common Shares
Minority Interest
Probability Of Bankruptcy
Understanding current and past Lexaria Bioscience Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Lexaria Bioscience's financial statements are interrelated, with each one affecting the others. For example, an increase in Lexaria Bioscience's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Lexaria Bioscience's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lexaria Bioscience Corp. Check Lexaria Bioscience's Beneish M Score to see the likelihood of Lexaria Bioscience's management manipulating its earnings.
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
Cash flow analysis captures how much money flows into and out of Lexaria Bioscience Corp. It measures of how well Lexaria is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Lexaria Bioscience brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Lexaria had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Lexaria Bioscience has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining Lexaria Bioscience's current stock value. Our valuation model uses many indicators to compare Lexaria Bioscience value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lexaria Bioscience competition to find correlations between indicators driving Lexaria Bioscience's intrinsic value. More Info.
Lexaria Bioscience Corp is rated third overall in return on equity category among its peers. It is rated fifth overall in return on asset category among its peers . At this time, Lexaria Bioscience's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lexaria Bioscience's earnings, one of the primary drivers of an investment's value.
Lexaria Bioscience Corp Systematic Risk
Lexaria Bioscience's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Lexaria Bioscience volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Lexaria Bioscience Corp correlated with the market. If Beta is less than 0 Lexaria Bioscience generally moves in the opposite direction as compared to the market. If Lexaria Bioscience Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Lexaria Bioscience Corp is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Lexaria Bioscience is generally in the same direction as the market. If Beta > 1 Lexaria Bioscience moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Lexaria Bioscience Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lexaria Bioscience's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Lexaria Bioscience growth as a starting point in their analysis.
Lexaria Bioscience November 30, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Lexaria Bioscience help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Lexaria Bioscience Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of Lexaria Bioscience Corp based on widely used predictive technical indicators. In general, we focus on analyzing Lexaria Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Lexaria Bioscience's daily price indicators and compare them against related drivers.
When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.